In low-dose tablet formulations containing quinoctone at unit strengths below 5 mg, segregation-induced content uniformity drift dominates the process risk profile, and direct compression is only acceptable when the milled active pharmaceutical ingredient presents a D90 of ≤ 150 µm and a D50 from 20 µm to 60 µm by laser diffraction per USP <429>. The API is passed through a Comil conical mill fitted with a 0.5 mm rasping screen at 1200 rpm to eliminate agglomerates, and the powder-flow function coefficient is measured on a Jenike shear cell; values below 4.0 trigger wet granulation or roller compaction because the blend will not discharge uniformly from the hopper at press speeds above 20 rpm. Geometric dilution is performed in a bin blender at 8 rpm for 15 min per dilution stage, first to a 10% w/w pre-blend with lactose monohydrate, then to a 1% final blend to avoid high-potency pockets. The tableting matrix contains microcrystalline cellulose, croscarmellose sodium at 2.0–4.0% w/w, colloidal silicon dioxide at 0.5% w/w, and sodium stearyl fumarate at 0.5–1.0% w/w; the lubricant is added last because over-lubrication above 1.0% prolongs disintegration time and reduces tensile strength. Compression is carried out on a rotary tablet press with 8 mm B-tooling, a compression force window of 8–18 kN, target hardness of 50–100 N, and ejection force below 500 N to prevent picking and lamination. Blend uniformity is assessed using a sampling thief at 10 locations; assay RSD must remain ≤ 5.0% before compression. Content uniformity testing follows USP <905> or Ph. Eur. 2.9.40 with an acceptance value ≤ 15.0. Dissolution is run on USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 M hydrochloric acid at 37.0°C; a Q value of ≥ 75% at 45 min is applied for immediate-release veterinary tablets unless a different release rate is justified by target-species data. Non-sterile oral tablet microbial quality follows Ph. Eur. 5.1.4; total aerobic microbial count is limited to ≤ 10³ CFU/g and total moulds/yeasts to ≤ 10² CFU/g. If the API demonstrates moisture uptake above 2% at 60% RH, tablets are packed in aluminium–aluminium blisters with a desiccant rather than PVC blisters, because moisture ingress above 3% shifts tablet hardness and dissolution profile.

What Limits Terminal Sterilisation of Quinoctone Parenterals at F0 ≥ 12 min?

Parenteral quinoctone solutions are processed under two distinct sterility-assurance routes, and the selection is governed by thermal degradation rather than microbiological control alone. The quinoxaline-di-N-oxide nucleus of quinoctone is susceptible to alkaline hydrolysis and can undergo reduction under high-temperature processing; published forced degradation data for this specific injectable matrix are limited, so preformulation studies are mandatory before an F0 is fixed. If terminal steam sterilisation is viable, the product is filled into Type I glass vials and sterilised at 121°C with F0 ≥ 12 min; the pH is maintained at 4.0–5.5 with a citrate buffer because alkaline conditions accelerate degradation. Bulk solution is sparged with nitrogen until dissolved oxygen is ≤ 0.5 mg/L; headspace oxygen is held below 2%. Sodium metabisulfite is added at 0.05–0.1% w/v as an antioxidant, and its residual concentration is monitored because excess sulfite can interfere with redox-sensitive analytes. For heat-labile formulations, aseptic filtration through a 0.22 µm PVDF or PES membrane is used, with pre-filtration through 0.45 µm to reduce bioburden; filter integrity is tested by bubble point or diffusion before and after filling. Pre-sterilisation bioburden is controlled to ≤ 10 CFU/100 mL. Subvisible particulate matter is measured per USP <788> or Ph. Eur. 2.9.19; for small-volume injections the threshold is not more than 6000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container, while large-volume parenterals are controlled to 25 and 3 particles per mL respectively. Sterility testing follows USP <71> or Ph. Eur. 2.6.1 by membrane filtration. Bacterial endotoxin is tested per USP <85> or Ph. Eur. 2.6.14; the limit is dose-derived from K/M, with K typically 5 EU/kg for parenteral veterinary products, but the final value is species-specific. Container closure integrity is confirmed by vacuum decay or dye ingress per USP <1207>. If lyophilised, the cake is dried to residual moisture <3.0% and the reconstituted solution is checked for turbidity ≤ 5 NTU before administration.

Powder-filled capsule processes for quinoctone API at fill weights below 250 mg begin with control of blend bulk density and flow because tamping-pin capsule machines require stable plug formation at bulk density 0.55–0.75 g/mL and tap density 0.75–0.95 g/mL. The fill blend typically combines milled quinoctone with lactose monohydrate, maize starch 1500, and silicon dioxide at 0.5–1.0% w/w; a 0.8 mm sieve is used before charging. Hard gelatin capsule shells with equilibrium moisture 13–16% are suitable only when the API moisture uptake remains below 2% at 60% RH; otherwise HPMC shells conditioned to 3–6% moisture are substituted to prevent brittle shell defects. A Bosch GKF 1500 tamping-pin machine is operated at 60–80% of rated capacity, and fill weight RSD is held ≤ 2.0% with in-process sampling every 15 min. Dissolution is performed on USP <711> apparatus 2 at 50 rpm with a capsule sinker; the same Q ≥ 75% at 45 min threshold is used unless the formulation is explicitly designed for modified release. Cross-contamination control on the capsule line requires dust extraction at the empty-capsule orienting station and periodic cleaning of tamping pins to avoid API carryover between batches.

Dispersible Powder Wetting Kinetics and Sedimentation Control at 20°C

Before wetting agents are selected, a dispersible quinoctone powder for drinking water is evaluated by pouring a 10 g dose into 500 mL of tap water at 20°C without stirring; acceptable wetting is ≤ 30 s, after which a low-shear stir at 500 rpm for 1 min must produce a homogeneous suspension or solution. The carrier is anhydrous dextrose or spray-dried lactose with bulk density 0.50–0.70 g/mL; poloxamer 188 or polysorbate 80 is added at 0.05–0.2% w/w to reduce floating and crusting. Sodium lauryl sulfate is usually avoided because foam generation exceeds 20 mm in a 1000-mL graduated cylinder after 1 min of stirring, which complicates automatic drinking lines. Water hardness of 200–400 mg/L CaCO3 can reduce performance through mineral binding or turbidity development; EDTA at 0.01% is incorporated only where compatibility with target species is demonstrated. Finished sachets use LDPE/aluminium/polyester laminate with water vapour permeability <0.1 g/m²·24 h at 38°C/90% RH and oxygen permeability <1.0 cm³/m²·24 h·atm. Reconstituted solution is required to maintain assay within 95–105%, pH shift ≤ 0.2, and turbidity ≤ 5 NTU per ISO 7027 after 24 h at 25°C; formulations failing this hold-time requirement are rejected for multi-day field use.

When Granule Friability Exceeds 1.0% After Pneumatic Conveying, Segregation Risk Rises

At loadings above 100 mg/g, dry powder segregation shifts quinoctone distribution toward the fine fraction, so granulation is used to lock the API into particles of 300–850 µm. A high-shear mixer is operated with impeller speed 200–400 rpm and chopper 1500–3000 rpm; povidone K30 solution is added at 2–5% w/w of dry charge until endpoint granule size is reached. Drying is performed in a fluid bed with inlet air 55–70°C, product temperature 30–45°C, and loss on drying targeted at 1.5–3.0% per USP <731>. Granule friability is measured by vibration on an 850 µm sieve for 20 min; retained fraction must remain ≥ 95%, because attrition below that value releases fines that segregate during bin discharge. Dilute-phase pneumatic conveying is limited to air velocity 15–20 m/s and bend radius 10× duct diameter to reduce impact damage. If the API is moisture-sensitive, granulation water is kept below 5% of dry charge and drying is initiated immediately after massing to avoid hydrolytic degradation at the granule surface.

In medicated feed premix production, two-stage serial dilution is mandatory because direct addition of neat quinoctone API to a horizontal ribbon mixer produces assay RSD values above 10% and uncontrolled dust exposure. The first dilution uses calcium carbonate or ground rice hulls with bulk density 0.4–0.7 g/cm³; soybean oil at 1–3% w/w is added to bind residual fine particles and reduce dust. The horizontal ribbon mixer is loaded to 70–80% of rated capacity and operated at 40–80 rpm; mixing time is determined by sampling 10 points with a sampling thief, and release is not permitted until assay RSD ≤ 5%. Cross-contamination is managed because quinoctone is not approved for all species or all regional use patterns; a flush of 5–10 kg carrier is run after each batch, and residual active substance in the subsequent non-medicated feed is controlled below 1% of the minimum therapeutic inclusion, with an HPLC limit of quantitation of 0.1 mg/kg in feed. Where premix is placed on the EU market, the carryover prevention and manufacturing rules of Regulation (EU) 2019/4 apply, and for substances without a harmonised carryover limit a site-specific risk assessment is required. Dedicated or segregated lines are used in regions where the compound is not approved for food-producing species, and operator exposure is controlled by vacuum transfer, local exhaust ventilation, and air-purifying respirators.

pH-Dependent Precipitation and Oxidative Stability in Solution Formulations

Prior to pH adjustment, the solubility curve of quinoctone is mapped across pH 2.0–8.0 at 25°C and 37°C; if solubility falls below 1 mg/mL at pH 6.5, oral solution dilution into drinking water risks precipitation and uneven dose intake. For acid-stable formulations, citrate buffer is added at 10–50 mM to hold pH at 4.0–5.5; phosphate buffer is avoided where hard water contains calcium or magnesium because insoluble phosphate salts form and plug drinking nipples. Cosolvents are selected from propylene glycol 10–25% v/v, glycerol 10–20%, or PEG 400 10–15%; above these ranges palatability in swine and poultry deteriorates, and parenteral haemocompatibility must be re-evaluated. Oxidative protection is provided by sodium metabisulfite 0.05–0.1% w/v, EDTA 0.01%, and nitrogen sparging to dissolved oxygen ≤ 0.5 mg/L. Packaging is amber Type I glass or opaque HDPE with an oxygen barrier; long-term storage conditions are set to 25°C/60% RH for climatic zones I and II or 30°C/65% RH for zones III and IV under VICH GL3. If terminal sterilisation is not feasible, the solution is filtered through 0.22 µm under aseptic conditions; if terminal sterilisation is feasible, F0 is set between 8 min and 12 min only after forced-degradation data confirm that assay loss remains ≤ 5% and degradation products stay within identification thresholds.